代谢类新药诊治和预防原发性肝癌的研究进展  

Advances on new metabolic drugs for diagnosis,treatment and prevention of primary hepato‐carcinoma

作　　者：钟瑜 包仕廷 ZHONG Yu;BAO Shi-ting(Guangdong Medical University,Zhanjiang 524023,China;Affiliated Hospital of Guangdong Medical University,Zhanjiang 524001,China)

机构地区：[1]广东医科大学,广东湛江524023 [2]广东医科大学附属医院,广东湛江524001

出　　处：《广东医科大学学报》2022年第2期238-241,共4页Journal of Guangdong Medical University

摘　　要：人体代谢与原发性肝癌发生发展存在密切联系;一旦发生代谢障碍,将进一步增加原发性肝癌发生率,并影响患者预后。目前一般认为代谢类药物对提高原发性肝癌的防治效果具有一定意义。该文综述了近年来代谢类药物在原发性肝癌治疗和预防中研究进展。Human metabolism is closely related to the occurrence and development of primary hepatocarcinoma.Once the metabolic disorders occur,it will further increase the incidence of primary hepatocarcinoma and affect the patients'prognosis.It is generally believed that the administration of metabolic drugs can improve the prevention and treatment of primary liver cancer.This article reviews the research progress of metabolic drugs in the treatment and prevention of primary hepatocarcinoma in recent years.

关 键 词：代谢药物 原发性肝癌 综述 

分 类 号：R735.7[医药卫生—肿瘤]